Transcenta Holding Announces Licensing Agreement with Lilly

瑞士迅达集团子公司 HJB 获礼来制药骨科治疗药物授权及大中华区销售权

2019-04-01 15:25:00 BioSpace

本文共727个字,阅读需2分钟

Transcenta Holding today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China, including the phase 2-completed Blosozumab, a humanized antibody to sclerostin. Transcenta will be responsible for the overall preclinical/clinical development, regulatory filing and manufacture of these biologic therapeutics. As part of this transaction, Lilly will receive an upfront payment in cash plus equity shares in Transcenta, and will be eligible for potential regulatory and sales milestones, and commercial royalty payments. Blosozumab has been studied by Lilly as a potential treatment for osteoporosis. It is the second novel biotherapeutics in anti-sclerostin class to have completed phase 2 clinical trials in the US and Blosozumab is expected to enter clinical trials in China next year. Several other novel biologic assets to treat bone diseases at earlier pre-clinical development stages are also included in this deal. "We are excited to sign this license agreement with Lilly, a global leader in innovative medicines with successful experience in the area of osteoporosis. This license demonstrates our commitment to developing innovative medicines to meet unmet medical needs in China," Transcenta's Executive Chairman Dr. Jonathan Zhao emphasized. "As a China-based biotherapeutics company, Transcenta is committed to discover and develop innovative medicines for meeting the unmet medical needs in China. China has a large number of patients with severe osteoporosis at risk of fracture. Our expertise in bone disease research and clinical development, process and manufacturing capability for antibody therapeutics, and strong investor support make us an ideal company to commercialize this innovative product in China," Transcenta's Chief Executive Officer Dr. Xueming Qian added. "Lilly is committed to working with capable companies around the world to develop meaningful treatments for patients," said Ruth Gimeno, Ph.D., Lilly vice president of diabetes and metabolic research. "We believe this transaction with Transcenta offers a great opportunity to potentially help patients in China that have osteoporosis and other bone issues."
超世达控股今日宣布,其全资附属公司 HJB 已与礼来公司签订独家协议,许可礼来公司在骨病治疗领域的一系列新生物治疗方案,用于大中华区的开发和商业化,其中包括第二期完成的 Blosozumab 。一种针对硬皮素的人源化抗体。Transcenta 将负责这些生物治疗药物的整体临床前/临床开发、监管备案和制造。作为本次交易的一部分,礼来(Lilly)公司将收到先锋达的现金加股权股份的预付款,并有资格获得潜在的监管和销售里程碑以及商业特许使用费。 礼来(Lilly)研究了 Blosozumab 作为骨质疏松症的潜在治疗方法。它是抗硬化类第二个新型生物治疗药物,已在美国完成2期临床试验, Blosozumab 有望于明年进入中国临床试验。本次交易还包括其他几项在临床前开发阶段用于治疗骨病的新型生物资产。 “我们很高兴与 Lilly 签署这项许可协议,礼来(Lilly)是在骨质疏松领域具有成功经验的创新药物的全球领导者。该许可证表明我们致力于开发创新药物,以满足中国未得到满足的医疗需求。 作为一家总部位于中国的生物治疗公司, Transcenta 致力于发现和开发创新药物,以满足中国未得到满足的医疗需求。我国有大量骨质疏松症患者存在骨折风险。我们在骨病研究和抗体治疗的临床开发、工艺和制造能力方面的专业知识,以及强大的投资者支持,使我们成为中国商业化这一创新产品的理想公司。 “ Lilly 致力于与世界各地有能力的公司合作,为患者开发有意义的治疗方法,”礼来(Lilly)糖尿病和代谢研究副总裁 Ruth Gimeno 博士说。“我们相信,此次与 Transcenta 的交易提供了一个巨大的机会,有可能帮助中国患有骨质疏松症和其他骨问题的患者。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文